Immuneactivation in neurodegenerative diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00007914

Enrollment

Registered

2015-03-25

Start date

2006-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F00 F03

Interventions

Group 1: Patients with dementia (either Alzheimer`s disease or MCI): Beneuran compositum tablets (50mg vitamin B1, 50 mg vitamin B6, 5mg folic acid and 0.05mg vitamin B12) 1 tablet/d for one month, af

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients: Criteria for Alzheimers disease (NINDS ADRDA) and mild cognitive impairment (Petersen et al). controls: age above 18, healthy controls

Exclusion criteria

Exclusion criteria: for all: Psychiatric diseases (other then dementia) metabolic diseases Neurodegenerative diseases other then dementia Vitaminsupplementation for the last 6 weeks

Design outcomes

Primary

Measure	Time frame
Explorative study. primary outcomes: levels of immuneactivation between subgroups at baseline and after three months (determination as described in pubished trials)	—

Secondary

Measure	Time frame
Correlation between clinical parameters (mini mental status examination) and laboratory markers (neopterin, folic acid, malondialdehyde, kynureine, vitamin b12, tryptophan, carbonyl proteins) at baseline and after three months of supplementation	—

Countries

Austria

Contacts

Public ContactPaulus Rommer

Medizinische Universität WienUniversitätsklinik für Neurologie

paulus.rommer@meduniwien.ac.at043 1 40400 31170

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026